General
Preferred name
FLIBANSERIN
Synonyms
BIMT-17BS ()
Girosa ()
BIMT-17 ()
Flibanserin ()
FLIBANSERIN HYDROCHLORIDE ()
BIMT-17, BIMT-17-BS ()
Flibanserine ()
Flibanserina ()
Ectris ()
BIMT 17 ()
BIMT-17-BS ()
BIMT 17 BS ()
Addyi ()
Flibanserin-d4 (hydrochloride) ()
P&D ID
PD009349
CAS
167933-07-5
147359-76-0
2748630-46-6
Tags
available
drug
Approved by
FDA
First approval
2015
Drug indication
Mood disorder
prostate adenocarcinoma
Female sexual arousal dysfunction
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION Flibanserin has an absolute oral availability of 33%.;
DESCRIPTION Flibanserin is reported as a serotonin 5-HT1A agonist and 5-HT2A antagonist . The compound was originally investigated as a antidepressant . (GtoPdb)
DESCRIPTION Flibanserin (BIMT-17; BIMT-17BS) is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research[1]-[5].
PRICE 48
DESCRIPTION Flibanserin, a benzimidazole derivative, has been found to be a Serotonin 1A/2A receptor agonist that was once studied as antidepressant as well as anxiolytic agent and could be used against female sexual dysfunction. (BOC Sciences Bioactive Compounds)
DESCRIPTION Flibanserin (Girosa) is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury. (TargetMol Bioactive Compound Library)
DESCRIPTION Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist that was developed for the treatment of hypoactive sexual desire disorder in women. (BOC Sciences Bioactive Compounds)
Compound Sets
20
Axon Medchem Screening Library
1499
BOC Sciences Bioactive Compounds
flibanserin-cas-167933-07-5-item-85488
flibanserin-hydrochloride-cas-147359-76-0-166878
Cayman Chemical Bioactives
19203
26779
ChEMBL Approved Drugs
CHEMBL231068
ChEMBL Drugs
CHEMBL231068
Drug Repurposing Hub
DrugBank
DB04908
DrugBank Approved Drugs
DB04908
DrugCentral
5022
DrugCentral Approved Drugs
5022
DrugMAP
DM70DTN
DrugMAP Approved Drugs
DM70DTN
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EOS101706
Guide to Pharmacology
8182
MedChem Express Bioactive Compound Library
HY-A0095
NCATS Inxight Approved Drugs
96XTC36K1B
ReFrame library
Selleckchem Bioactive Compound Library
flibanserin
TargetMol Bioactive Compound Library
T4297
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
390.17
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
3
cLogP
3.17
TPSA
44.27
Fraction CSP3
0.35
Chiral centers
0.0
Largest ring
6.0
QED
0.74
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
5-HT Receptor
5-HT1A
5-HT2A
D4
DRD4, HTR1A, HTR2A
5-HT1A ago./5-HT2A antag.
Indication
hypoactive sexual desire disorder
MOA
serotonin receptor agonist
Pathway
GPCR/G protein
Neuronal Signaling
Neuroscience
Source data